Compounds > enbucrilate
Page last updated: 2024-08-22

enbucrilate and enkephalin, leucine-2-alanine

enbucrilate has been researched along with enkephalin, leucine-2-alanine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's5 (83.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cecchelli, R; Chauvet, R; Couet, W; Fenart, L; Olivier, JC; Pariat, C1
Sabel, BA; Schroeder, H; Schroeder, U1
Alyaudtin, RN; Begley, DJ; Kreuter, J; Löbenberg, R; Ramge, P; Reichel, A1
Alyautdin, R; Begley, DJ; Engelhardt, B; Gelperina, SE; Hamm, S; Kreuter, J; Petrov, V; Ramge, P; von Briesen, H1
Das, D; Lin, S1
Alyautdin, RN; Petrov, VE; Shamenkov, DA1

Other Studies

6 other study(ies) available for enbucrilate and enkephalin, leucine-2-alanine

ArticleYear
Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
    Pharmaceutical research, 1999, Volume: 16, Issue:12

    Topics: Analgesics; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Chromatography, High Pressure Liquid; Enbucrilate; Endothelium; Enkephalin, Leucine-2-Alanine; Excipients; Male; Mice; Microspheres; Motor Activity; Pain Measurement; Polysorbates

1999
Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
    Life sciences, 2000, Volume: 66, Issue:6

    Topics: Animals; Biological Availability; Blood-Brain Barrier; Drug Carriers; Enbucrilate; Enkephalin, Leucine-2-Alanine; Injections, Intravenous; Male; Mice; Tissue Distribution; Tritium

2000
Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
    Journal of drug targeting, 2001, Volume: 9, Issue:3

    Topics: Analgesics; Animals; Blood-Brain Barrier; Brain; Drug Delivery Systems; Drug Interactions; Enbucrilate; Enkephalin, Leucine-2-Alanine; Female; Male; Mice; Particle Size; Polysorbates; Rats

2001
Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
    Pharmaceutical research, 2003, Volume: 20, Issue:3

    Topics: Analgesics, Opioid; Animals; Astrocytes; Blood-Brain Barrier; Brain; Capillaries; Cattle; Cells, Cultured; Drug Carriers; Enbucrilate; Endothelium, Vascular; Enkephalin, Leucine-2-Alanine; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred ICR; Microscopy, Electron; Models, Biological; Nanotechnology; Particle Size; Polysorbates; Rats

2003
Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
    Journal of pharmaceutical sciences, 2005, Volume: 94, Issue:6

    Topics: Administration, Oral; Analgesics; Animals; Blood-Brain Barrier; Brain; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Stability; Enbucrilate; Enkephalin, Leucine-2-Alanine; Female; Mice; Nanostructures; Polyethylene Glycols; Solubility

2005
Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
    Bulletin of experimental biology and medicine, 2006, Volume: 142, Issue:6

    Topics: Adsorption; Analgesics; Animals; Animals, Outbred Strains; Apolipoproteins B; Apolipoproteins E; Behavior, Animal; Biological Transport; Blood-Brain Barrier; Coated Materials, Biocompatible; Drug Carriers; Drug Delivery Systems; Enbucrilate; Enkephalin, Leucine-2-Alanine; Mice; Nanoparticles; Particle Size; Polysorbates; Time Factors

2006